Genomic studies of urothelial carcinoma have identified inactivation of tumor suppressor genes (e.g., TP53, ARID1A) and activation of oncogenes (e.g., FGFR3, PIK3CA). 3′ RACE is a useful method for identifying gene fusions and alterations in urothelial cancers, particularly those involving FGFR family genes, which can be targeted by therapies like erdafitinib.
Recently, scientists from the Petrov Research Institute of Oncology and St. Petersburg Pediatric Medical University published a study in International Journal of Molecular Sciences. By using GeneMind GenoLab M high throughput sequencing platform, they developed a panel sequencing technique based on 3′ RACE. This panel covers key treatment-related genes (FGFR1-4, KRAS, NRAS, BRAF, ERBB2, CD274, and PIK3CA) and was used to analyze 233 patient samples, revealing mutation profiles of druggable genes in urothelial carcinoma.
